[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100476984":3},{"organization":4,"outcomesModule":7,"designInfo":68,"detailedDescription":69,"studyPopulation":72,"armGroups":73,"interventions":78,"overallOfficials":69,"centralContacts":84,"locations":94,"responsibleParty":111,"collaborators":69,"id":113,"slug":69,"hasResults":114,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":69,"eligibilityCriteria":118,"healthyVolunteers":114,"sex":119,"minAge":120,"maxAge":69,"enrollmentInfo":121,"targetDuration":69,"studyType":124,"phases":69,"briefSummary":125,"conditions":126,"keywords":69,"overallStatus":128,"whyStopped":69,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":138},{"fullName":5,"class":6},"Pierre Fabre Medicament","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":51},[9,13],{"measure":10,"description":11,"timeFrame":12},"Duration of Treatment","Median duration of extended adjuvant treatment with neratinib","12 months of treatment",{"measure":14,"description":15,"timeFrame":12},"Treatment holds and permanent discontinuations time","Median treatment holds and permanent discontinuations time",[17,21,24,27,30,33,36,39,42,45,48],{"measure":18,"description":19,"timeFrame":20},"Patient demographics","% of patients with different demographic characteristics","Baseline",{"measure":22,"description":23,"timeFrame":20},"Patient characteristics","% of patients with different disease characteristics",{"measure":25,"description":26,"timeFrame":20},"Time to treatment","Median time to treatment since completion of adjuvant regimen",{"measure":28,"description":29,"timeFrame":20},"Prior adjuvant treatments","% of patients with different prior adjuvant treatments",{"measure":31,"description":32,"timeFrame":12},"Dose adjustments","% of patients with dose adjustments",{"measure":34,"description":35,"timeFrame":12},"Dose intensity","Absolute and relative dose intensity",{"measure":37,"description":38,"timeFrame":12},"Concomitant medication","% of patients with different concomitant medications",{"measure":40,"description":41,"timeFrame":12},"Incidence of AESI","Incidence of all grades of adverse events of special interest (AESI)",{"measure":43,"description":44,"timeFrame":12},"Type of AESI","% of different type of all grades of adverse events of special interest (AESI)",{"measure":46,"description":47,"timeFrame":12},"Severity of AESI","% of patients with adverse events by severity",{"measure":49,"description":50,"timeFrame":12},"action taken for AESI","% of patients with action taken against adverse events",[52,56,59,62,65],{"measure":53,"description":54,"timeFrame":55},"Time of recurrence","Time from end of neratinib treatment to first invasive recurrence","12 months of treatment； 12 months of follow-up",{"measure":57,"description":58,"timeFrame":55},"Recurrent site","% of different site of invasive tumor recurrence",{"measure":60,"description":61,"timeFrame":55},"Recurrent size","% of different size of invasive tumor recurrence",{"measure":63,"description":64,"timeFrame":12},"QoL - EQ-5D-5L","Median score of the EQ-5D-5L during neratinib treatment. EQ-5D-5L scale as self-reported health-related quality of life.",{"measure":66,"description":67,"timeFrame":12},"QoL - FACIT D","Median score of the FACIT D during neratinib treatment. FACIT D scale as self-reported health-related quality of life.",{"allocation":69,"interventionModel":69,"interventionModelDescription":69,"primaryPurpose":69,"observationalModel":70,"timePerspective":71,"maskingInfo":69},null,"CASE_ONLY","PROSPECTIVE","Patients assigned extended adjuvant treatment with neratinib for 12 months for their HER2-positive, early-stage breast cancer.",[74],{"label":75,"type":69,"description":69,"interventionNames":76},"Neratinib extended ajuvant treatmeng for 1 year",[77],"Drug: Neratinib",[79],{"type":80,"name":81,"description":82,"armGroupLabels":83,"otherNames":69},"DRUG","Neratinib","Neratinib standard dose 240 mg once daily for 1 year",[75],[85,90],{"name":86,"role":87,"phone":88,"phoneExt":69,"email":89},"Huanying Zhen, Master","CONTACT","+86010-8534-7209","nlx-pms@pierre-fabre.com",{"name":91,"role":87,"phone":92,"phoneExt":69,"email":93},"Shujie Pei, Master","+86-13648686390","shujie.pei@clinflash.com",[95],{"facility":96,"status":69,"city":97,"state":69,"zip":69,"country":98,"countryCode":99,"cosmosGeoPoint":100,"geoPoint":105,"contacts":106},"Medical Affair","Shanghai","China","CN",{"type":101,"coordinates":102},"Point",[103,104],121.45806,31.22222,{"lat":104,"lon":103},[107,109],{"name":86,"role":87,"phone":108,"phoneExt":69,"email":89},"010-85347209",{"name":91,"role":87,"phone":92,"phoneExt":69,"email":110},"Shujie.pei@clinflash.com",{"type":112,"investigatorFullName":69,"investigatorTitle":69,"investigatorAffiliation":69,"oldNameTitle":69,"oldOrganization":69},"SPONSOR","100476984",false,"NCT05491057","Treatment Patterns of Neratinib in HER2+ EBC in China","A Multicenter, Open-label, Single-arm, Non-interventional Study to Investigate the Treatment Patterns of Nerlynx® (Neratinib) in HER2-positive Early-stage Breast Cancer in China","Inclusion Criteria:\n\n* Signed written informed consent approved by the reviewing Ethics Committee (EC).\n* Adult patients (≥18 years of age, no upper limit).\n* Eligible to receive neratinib for extended adjuvant treatment as per prescribing information in China, diagnosed with HER2 overexpressing\u002Famplified early-stage breast cancer regardless of hormone receptor (HR) status and clinical\u002Fradiological assessed to be negative for recurrences or metastatic disease.\n\nExclusion Criteria:\n\n* Presence of any contraindication with regard to the neratinib treatment.\n* Current or upcoming participation in an interventional clinical trial. (Investigational treatment within four weeks of enrolment).","ALL","18 Years",{"count":122,"type":123},500,"ESTIMATED","OBSERVATIONAL","This is a multicenter, open-label, single-arm, non-interventional study to investigate the treatment patterns of Neratinib in HER2-positive early-stage breast cancer in China",[127],"Breast Cancer","NOT_YET_RECRUITING","2022-08-04",{"date":131,"type":132},"2022-08-08","ACTUAL",{"date":134,"type":123},"2022-09-30",{"date":136,"type":123},"2026-06-30",{"name":5,"class":6},1]